Search Results | Clinical Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer

Susan Slovin, Syed Hussain, Fred Saad, Jorge Garcia, Joel Picus, Roberta Ferraldeschi, Mateus Crespo, Penelope Flohr, Ruth Riisnaes, Chihche Lin, Harold Keer, Aram Oganesian, Paul Workman, Johann de Bono

Clin Cancer Res (2019) 25 (15): 4624–4633.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-3212

Published: 01 August 2019

View article

Includes: Supplementary data

Journal Articles

HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target

Jacqueline H.L. Fok, Somaieh Hedayat, Lei Zhang, Lauren I. Aronson, Fabio Mirabella, Charlotte Pawlyn, Michael D. Bright, Christopher P. Wardell, Jonathan J. Keats, Emmanuel De Billy, Carl S. Rye, Nicola E.A. Chessum, Keith Jones, Gareth J. Morgan, Suzanne A. Eccles, Paul Workman, Faith E. Davies

Clin Cancer Res (2018) 24 (10): 2395–2407.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1594

Published: 14 May 2018

View article

Journal Articles

Abstract IA16: Targeting molecular chaperone and stress pathways to hit multiple hallmarks and overcome resistance

Paul Workman

Clin Cancer Res (2017) 23 (1_Supplement): IA16.

DOI: https://doi.org/10.1158/1557-3265.PMCCAVULN16-IA16

Published: 02 January 2017

View article

Journal Articles

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Clin Cancer Res (2015) 21 (1): 77–86.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-0947

Published: 05 January 2015

View article

Includes: Supplementary data

Journal Articles

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies: experience and recommendations

Paul Workman, Hayley Farmer, Eric O. Aboagye, Yuen L. Chung, John R. Griffiths, Rachel Hart, Martin O. Leach, Ross J. Maxwell, Paul M. McSheehy, Pat M. Price, Jamal Zweit

Clin Cancer Res (2006) 12 (19_Supplement): B73.

Published: 15 August 2014

View article

Journal Articles

Drugging the cancer genome: Advances, challenges, and the pharmacologic audit trail

Paul Workman

Clin Cancer Res (2006) 12 (19_Supplement): PL-32.

Published: 15 August 2014

View article

Journal Articles

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Clin Cancer Res (2012) 18 (14): 3912–3923.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-3313

Published: 15 July 2012

View article

Includes: Supplementary data

Journal Articles

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

Len Neckers, Paul Workman

Clin Cancer Res (2012) 18 (1): 64–76.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-1000

Published: 02 January 2012

View article

Journal Articles

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

Simon Pacey, Richard H. Wilson, Mike Walton, Martin M. Eatock, Anthea Hardcastle, Anna Zetterlund, Hendrik-Tobias Arkenau, Javier Moreno-Farre, Udai Banerji, Belle Roels, Heidi Peachey, Wynne Aherne, Johan S. de Bono, Florence Raynaud, Paul Workman, Ian Judson

Clin Cancer Res (2011) 17 (6): 1561–1570.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-1927

Published: 15 March 2011

View article

Includes: Supplementary data

Journal Articles

EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines

Dorine A. Bax, Nathalie Gaspar, Suzanne E. Little, Lynley Marshall, Lara Perryman, Marie Regairaz, Marta Viana-Pereira, Raisa Vuononvirta, Swee Y. Sharp, Jorge S. Reis-Filho, João N. Stávale, Safa Al-Sarraj, Rui M. Reis, Gilles Vassal, Andrew D.J. Pearson, Darren Hargrave, David W. Ellison, Paul Workman, Chris Jones

Clin Cancer Res (2009) 15 (18): 5753–5761.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-3210

Published: 14 September 2009

View article

Includes: Supplementary data

Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Johann S. de Bono, Rebecca Kristeleit, Anthony Tolcher, Peter Fong, Simon Pacey, Vasilios Karavasilis, Monica Mita, Heather Shaw, Paul Workman, Stan Kaye, Eric K. Rowinsky, Wynne Aherne, Peter Atadja, Jeffrey W. Scott, Amita Patnaik

Clin Cancer Res (2008) 14 (20): 6663–6673.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-0376

Published: 16 October 2008

View article

Journal Articles

Biomarkers In Early Clinical Trials: the Committed and the Skeptics

Udai Banerji, Johann de Bono, Ian Judson, Stanley Kaye, Paul Workman

Clin Cancer Res (2008) 14 (8): 2512.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-5224

Published: 15 April 2008

View article

Journal Articles

Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models

Udai Banerji, Michael Walton, Florence Raynaud, Rachel Grimshaw, Lloyd Kelland, Melani Valenti, Ian Judson, Paul Workman

Clin Cancer Res (2005) 11 (19): 7023–7032.

DOI: https://doi.org/10.1158/1078-0432.CCR-05-0518

Published: 03 October 2005

View article

Includes: Supplementary data

Journal Articles

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

Florence I. Raynaud, Steven R. Whittaker, Peter M. Fischer, Steven McClue, Michael I. Walton, S. Elaine Barrie, Michelle D. Garrett, Paul Rogers, Simon J. Clarke, Lloyd R. Kelland, Melanie Valenti, Lisa Brunton, Suzanne Eccles, David P. Lane, Paul Workman

Clin Cancer Res (2005) 11 (13): 4875–4887.

DOI: https://doi.org/10.1158/1078-0432.CCR-04-2264

Published: 06 July 2005

View article

Journal Articles

Gene Expression Profiling after Radiation-Induced DNA Damage Is Strongly Predictive of BRCA1 Mutation Carrier Status

Zsofia Kote-Jarai, Richard D. Williams, Nicola Cattini, Maria Copeland, Ian Giddings, Richard Wooster, Robert H. tePoele, Paul Workman, Barry Gusterson, John Peacock, Gerald Gui, Colin Campbell, Ros Eeles

Clin Cancer Res (2004) 10 (3): 958–963.

DOI: https://doi.org/10.1158/1078-0432.CCR-1067-3

Published: 10 February 2004

View article

Journal Articles

A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy

Beatrice M. Seddon, Geoffrey S. Payne, Laura Simmons, Ruth Ruddle, Rachel Grimshaw, Siew Tan, Alison Turner, Florence Raynaud, Gavin Halbert, Martin O. Leach, Ian Judson, Paul Workman

Clin Cancer Res (2003) 9 (14): 5101–5112.

Published: 12 November 2003

View article

Journal Articles

Validation of the Fluorinated 2-Nitroimidazole SR-4554 as a Noninvasive Hypoxia Marker Detected by Magnetic Resonance Spectroscopy

Beatrice M. Seddon, Ross J. Maxwell, Davina J. Honess, Rachel Grimshaw, Florence Raynaud, Gillian M. Tozer, Paul Workman

Clin Cancer Res (2002) 8 (7): 2323–2335.

Published: 01 July 2002

View article

Journal Articles

Establishment and Characterization of Acquired Resistance to the Farnesyl Protein Transferase Inhibitor R115777 in a Human Colon Cancer Cell Line

Victoria Smith, Martin G. Rowlands, Elaine Barrie, Paul Workman, Lloyd R. Kelland

Clin Cancer Res (2002) 8 (6): 2002–2009.

Published: 01 June 2002

View article

Journal Articles

Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer

Lloyd R. Kelland, Vicki Smith, Melanie Valenti, Lisa Patterson, Paul A. Clarke, Simone Detre, Dave End, Angela J. Howes, Mitch Dowsett, Paul Workman, Stephen R. D. Johnston

Clin Cancer Res (2001) 7 (11): 3544–3550.

Published: 01 November 2001

View article

NARROW

Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer

HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target

Abstract IA16: Targeting molecular chaperone and stress pathways to hit multiple hallmarks and overcome resistance

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies: experience and recommendations

Drugging the cancer genome: Advances, challenges, and the pharmacologic audit trail

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Biomarkers In Early Clinical Trials: the Committed and the Skeptics

Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

Gene Expression Profiling after Radiation-Induced DNA Damage Is Strongly Predictive of BRCA1 Mutation Carrier Status

A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy

Validation of the Fluorinated 2-Nitroimidazole SR-4554 as a Noninvasive Hypoxia Marker Detected by Magnetic Resonance Spectroscopy

Establishment and Characterization of Acquired Resistance to the Farnesyl Protein Transferase Inhibitor R115777 in a Human Colon Cancer Cell Line

Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only